Recearch and Education

Educational activities

• Monographic seminars and training workshops combining both theory and practice. These are based on the monographic scientific meetings.

Research

• Research Programmes carried out at Universities, Hospitals and Private Organizations funded by private and public agencies.
• Scientific Exchange Programmes between Universities and Hospitals within the Spanish territory and abroad.
• Scientific Quality Evaluation Programmes on a specific area or topic.
• Scholarships. The awarding of scholarships will be carried out within the foundation´s research programme, previously approved by the Fundación Cerebro y Mente.

Funded Research Projects

The Fundacion Cerebro y Mente collaborates in projects funded by other agencies. This collaboration varies from one project to another, carrying out research work, participating in congresses, contributing to travel expenses or providing infrastructure such as logistic support, access to resources or publication of papers.

State funded projects externally assessed

• Standard pattern and genetic markers as risk factors associated to the permanent neuropsychological deterioration in extasis consumers. A Home Office project. National plan against drug addiction. Hospital Universitario 12 de Octubre. Department of Psychiatry.

• Study of brain anatomy and function in treatment resistant schizophrenia; relation to symptomatogy and response to clozapine. Comunidad Autónoma de Madrid.

• Clinical correlations, anatomy and functions of the brain studied with PET and NMR in first out-breaks schizophrenia. Relation to response to risperidone. Universidad Complutense de Madrid for the free use of the PET Centre Complutense.

• Study of brain anatomy and function in treatment resistant schizophrenia; relation to symptomatology and response to clozapine. Health Research Fund.

• Neurobiological factors and personality dimentions in alcoholism. Health Research Fund.

• Clinical, therapeutic and brain parameters in first out-break of schizophrenia. Health Research Fund.

• Molecular genetic markers of alcoholism clinical and evolutionary treats. Comunidad Autónoma de Madrid.

• Identification of neurobiological markers in alcoholism and relation to naltrexone. Clinical and Preclinical Studies.

• Pharmacological effects of antagonists of receptor cannabinoide CB1 . Funded by the Home Office. National plan against drug addiction.

• Neurobiological markers of vulnerability to alcohol following drug abuse and/or medication. Analysis of naltrexone al efficiency in alcoholism and drug abuse and/or medication. Study. Health Research Fund.

• Biochemical research on neurological illnesses. Instituto de salud Carlos III Health Research Fund.

• Live observation of the serotoninergic 5-HT1A receptor in alcoholic patients. Comunidad Autónoma de Madrid.

• The impact of depressive comorbility (and severe deterioration of cognoscitive functions) on hospitalized young and old patients being followed up in out-patient units. (N° G03/128). Instituto de Salud Carlos III. Health Research Fund.

• Molecular medical imaging and multimodality. (N° G03/185). Instituto de Salud Carlos III. Health Research Fund.

• Regulation of emotional response in male and female mice lacking the receptor cannabinoide CB1 gene.

• Comparative study of genetic-molecular markers between alcholism and pathological gambling, and its phenotypic expression.

Private agencies funded projects externally assessed.

• Neurodeteroration in first years of schizophrenia. Clinical study and volumatric MRI, P300 and MRI spectroscopy. Fundación La Caixa.

• The role of the receptor cannabinoide CB1 in animal models with Parkinson disease and study on the efficiency and complications of L-DOPA treatment or dopaminergic antagonists in mice lacking the receptor cannabinoide CB1 gene. Fundación La Caixa.

• Response to sertindol in schizophrenia. Clinical correlations, anatomy and functions of the brain studied with PET and NMR. Lundbeck pharmaceutical.

• Structural and functional brain alterations in midly developed schizophrenia . Relation to response to olanzapine. Lilly pharmaceuticals.

Research projects promoted between the Fundación Cerebro y Mente and the pharmaceutical industry.

Neuroimaging studies in schizophrenia

• Study of the cerebral, clinical and therapeutic parameters in first out-break schizophrenia.

• Observational and cohort study of sertindol in patients with schizophrenia.

• Study of the functions, structures and alterations of the brain in mildly developed schizophrenia. Relation to response to olanzapine.

• Study of multimodal neuroimaging in schizophrenia treated with ziprasidone: Response prediction, prevention of frontal deterioration and metabolic changes with this drug.

• The preparation of an approval form to consent to treatment for schizophrenia.

Study of clinical and genetic heterogeneity in addictions and impulse control.

• Identification of neurobiological markers in alcoholism and its regulation with naltrexone. Vulnerability to alcoholism following drug abuse and/or medication. Preclinical studies.

• Efficiency of naltrexone to block brain activity induced by cocaine or cannabinoide agonists. Studies of NMRf and regulation of the Genetic Expression in rat´s brain.

• Genetic polymorphism of the receptor cannabinoide CB1 and of the enzyme fatty acid amidohydrolase in obesity, annorexia nerviosa and bulima.

• Identification of neurological markers in alcoholism and its regulation with naltrexone. Vulnerability to alcohol following drug abuse and/or medication. Preclinical studies.

• Cabapentine and impulsivity in alcoholism.

• Prevalence of illnesses due to drug abuse in people diagnosed with hiperactivity and attention deficit disorder.

• Study of haplotypes in the dopaminergic type 2 (DRD2) receptor encoding gene in patients with schizophrenia in relation to biochemical and neuropsycological endophenotypes.

Neurotoxicity, neurodeterioration and neuroprotection

• Botulinum toxin treatment in dystonia, spasticity and other pathologies.

• Development of behavioral tests in mice following MPTP and neurim-like compounds.

Fundación Cerebro y Mente
c/ General Oraa, 47 - 1º E 28006 Madrid, España
Telf: +34 91 561 1267 Fax: +34 91 564 1817
http://www.cermente.com

© 2009 Fundación Cerebro y Mente. All rights reserved.